Today we have announced acquisition of Thirona Retina by Revenio Group Corporation’s subsidiary Icare Finland Oy.

After years of research and development, we are proud to have created a reliable, clinically validated product (RetCAD™), which has been consistently validated by independent clinical studies and has received strong customer reception across Europe and Asia-Pacific.

By joining forces with iCare, a market leader in eye care solutions, Thirona Retina is poised to enhance patient outcomes and drive innovation in eye care. Leveraging iCare’s market presence and expertise, Thirona Retina will now bring its cutting-edge AI-driven RetCAD™ technology—designed to screen fundus images for diabetic retinopathy, age-related macular degeneration, and glaucoma—to a wider global audience, revolutionizing eye care, integrated into iCare’s ILLUME and other retinal screening solutions.

Teaming up with iCare, who has been our valued distribution partner for several years, we are well geared to accelerate the adoption of RetCAD™ and broaden its impact on a global scale.

Read the full announcement here.